ALK

CROWN study: lorlatinib vs crizotinib in 1L NSCLC 5:28
CROWN study: lorlatinib vs crizotinib in 1L NSCLC
Sanjay Popat • 2 Oct 2020
ALTA-1L updates at ESMO 2020: intracranial efficacy and HRQoL 3:41
ALTA-1L updates at ESMO 2020: intracranial efficacy and HRQoL
Sanjay Popat
Updates in ALK+ NSCLC 10:43
Updates in ALK+ NSCLC
Ross Camidge • 26 Mar 2020
Management of frontline ALK+ NSCLC: brigatinib vs. alectinib 3:04
Management of frontline ALK+ NSCLC: brigatinib vs. alectinib
Riyaz Shah • 29 Jan 2020
Brain metastases in ALK+ NSCLC 2:35
Brain metastases in ALK+ NSCLC
Natasha Leighl • 29 Jan 2020
UK excels at molecular testing for lung cancer 0:51
UK excels at molecular testing for lung cancer
Riyaz Shah • 29 Jan 2020
Lung cancer molecular testing in the UK 4:38
Lung cancer molecular testing in the UK
Neal Navani • 30 Jan 2020
Lung cancer: actionable targets 4:16
Lung cancer: actionable targets
Samreen Ahmed • 31 Jan 2020
Current treatment landscape for ALK-positive NSCLC 2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
Biomarkers in NSCLC: a pathologist’s insight into PD-L1 and TMB 3:43
Biomarkers in NSCLC: a pathologist’s insight into PD-L1 and TMB
Alex Haragan • 25 Jan 2019
Challenges and treatment of CNS metastases in NSCLC 0:58
Challenges and treatment of CNS metastases in NSCLC
Sanjay Popat • 19 Oct 2018
Impact of new TKIs on NSCLC treatment planning 3:16
Impact of new TKIs on NSCLC treatment planning
Nicolas Girard • 11 Apr 2018
Optimizing treatment of ALK+ NSCLC: clinical realities 1:23
Optimizing treatment of ALK+ NSCLC: clinical realities
Silvia Novello • 11 Apr 2018
Therapy sequencing in the current NSCLC treatment landscape 1:34
Therapy sequencing in the current NSCLC treatment landscape
Nicolas Girard • 11 Apr 2018
Personalized therapy in thoracic malignancies 1:34
Personalized therapy in thoracic malignancies
Dean Fennell
A new role for pharmacists in the personalized treatment of cancer patients? 4:43
A new role for pharmacists in the personalized treatment of cancer patients?
Christine Walko • 21 Mar 2018
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals